Background : Anticancer drugs act by increasing intracellular hydrogen peroxide levels. Mangafodipir, a superoxide dismutase (SOD) mimic with catalase and glutathione reductase activities, protects normal cells from apoptosis induced by H 2 O 2 . We investigated its and other oxidative stress modulators' effects on anticancer drug activity in vitro and in vivo. Methods : Cell lysis and intracellular reactive oxygen species levels were assessed in vitro in human leukocytes from healthy subjects and in murine CT26 colon cancer cells. Cells were exposed to the chemotherapeutic agents paclitaxel, oxaliplatin, or 5-fl uorouracil, either in the presence or absence of mangafodipir and other oxidative stress modulators. 
Reactive oxygen species, such as superoxide anions, and hydrogen peroxide (H 2 O 2 ) are normal byproducts of cellular aerobic metabolism. Superoxide anions (O 2 − ) are secondarily converted to H 2 O 2 by the superoxide dismutases (SODs). H 2 O 2 has a dual role in cellular homeostasis. Low levels of intracellular H 2 O 2 stimulate cell growth ( 1 ) , whereas high levels of H 2 O 2 lead to cell senescence and apoptosis ( 2 , 3 ) . Several anticancer agents, such as 5-fl uorouracil ( 4 ) , platinum ( 5 , 6 ) , arsenic trioxide ( 7 ) , pac litaxel ( 8 ) , and anthracyclines ( 9 , 10 ) increase levels of reactive oxygen species. Tumor cells have higher levels of reactive oxygen species than normal cells and are therefore more sensitive to the additional oxidative stress generated by anticancer agents ( 5 , 6 , 11 ) .
Cells also contain a variety of free radical scavenging systems that protect them from the effects of drugs that generate oxygen free radicals. Catalase and glutathione peroxidase are enzymes that detoxify H 2 O 2 . High levels in tumor cells of reduced glutathione, the cofactor of glutathione peroxidase, have been associated with a multidrug resistance phenotype ( 12 ) . Recent studies have suggested that compounds that target such protective mechanisms could enhance the activity of anticancer agents and reverse the multidrug resistance phenotype. For example, buthionine sulfoximine (BSO), a glutathione synthesis inhibitor, can increase the cytotoxicity of melphalan by preventing glutathione peroxidase activity and increasing H 2 O 2 levels ( 13 ) . However, BSO depletes glutathione in both normal and cancer cells, which increases melphalan's hematologic toxicity and prevents any enhancement of the therapeutic index of this anticancer agent ( 14 , 15 ) . Conversely, N-acetylcysteine protects normal cells from the cytotoxic effects of anticancer drugs by preventing elevation of intracellular H 2 O 2 through its catalase-and glutathione reductase -like properties ( 6 ) .
SOD enzymes can also affect tumor cell proliferation via their effects on peroxide levels. Indeed, overexpression of SOD in human cancer cell lines increases H 2 O 2 production and reduces tumor growth in the absence of anticancer agents ( 16 , 17 ) . We have previously reported that two nonpeptidyl mimics of SOD, copper [II] diisopropylsalicylate (CuDIPS) and manganese [III] tetrakis- (5, 10, 15, 20) -benzoic acid porphyrin (MnTBAP), increase the cytotoxic activity of anticancer drugs by increasing H 2 O 2 levels ( 6 ) . In addition, mangafodipir, a contrast agent used in magnetic resonance imaging, can protect normal liver cells against reactive oxygen species -induced apoptosis ( 18 ) . Mangafodipir is a chelate of manganese [II] and of the ligand fodipir, a vitamin B6 derivate. Mangafodipir has SOD-, catalase-, and glutathione reductase -like properties, allowing it to act at multiple steps of the reactive oxygen species cascade.
We hypothesized that the association of those properties in a single molecule such as mangafodipir could be benefi cial through its ability to enhance the killing of cancer cells while protecting normal cells from chemotherapeutic toxicity. More specifi cally, we investigated the ability of mangafodipir to minimize the hematologic toxicity and potentiate the antitumor activity of several commonly used anticancer agents both in vitro and in vivo. The effects of mangafodipir were compared with those of CuDIPS, a Cu/ZnSOD mimic with no catalase or glutathione reductase activity ( 19 ) ; MnTBAP, a MnSOD mimic with catalase activity ( 20 ) ; and N-acetylcysteine, an antioxidant molecule that has both catalase and glutathione-reductase activities but not SOD activity ( 21 ) , in tumor cell lines, in human leukocytes, and in mice.
M ETHODS

Chemicals and Cell Lines
All chemicals were from Sigma (Saint Quentin Fallavier, France), except for mangafodipir (Teslascan; Amersham Health, Amersham, U.K.), oxaliplatin (Eloxatine; Sanofi -Aventis, Paris, France), docetaxel (Taxotere; Sanofi -Aventis), and paclitaxel (Taxol; Bristol Myers Squibb, Rueil Malmaison, France), for which commercial solutions were used. CT26 (mouse colon carcinoma, American Type Culture Collection [ATCC] 2638), Hepa1.6 (mouse liver hepatoma, ATCC 1830), and A549 (human lung carcinoma, ATCC CCL-185) cell lines were obtained from ATCC (Manassas, VA). Tumor cells were cultured in Dulbecco's modifi ed Eagle's medium -Glutamax-I (Life Technologies, Cergy Pontoise, France) supplemented with 10% heat-inactivated fetal calf serum (Life Technologies) and antibiotics. All cell lines were routinely tested to ensure that they were free of Mycoplasma infection.
Human Leukocytes
Human leukocytes were obtained from six healthy volunteers and 10 cancer patients. All cancer patients (eight women and two men) were diagnosed with metastatic or locally advanced solid tumors (breast [ n = 5], prostate [ n = 2], lung [ n = 1], stomach [ n = 1], and ovary [ n = 1]) and were part of a pharmacokinetic study of docetaxel reported elsewhere ( 22 ) . They had given written inform consent to an additional blood collection for the purpose of the present study. The study was approved by the Ethics Committee of Hopital Cochin, Paris. Ten milliliters of blood were collected before any antitumoral treatment, hemolyzed with 0.15 mM ammonium chloride, and then centrifuged at 1800 rpm (700 g ) for 5 minutes. The pellet was suspended in RPMI medium -Glutamax-I supplemented with 10% heat-inactivated fetal calf serum and antibiotics (complete medium). Leukocytes (5 × 10 4 cells/well) were then seeded in 96-well plates (Costar Corning, Inc., Corning, NY) and immediately exposed to anticancer agents and/or to oxidative stress modulators.
In Vitro Cell Viability Assays
Tumor cells (2 × 10 4 cells/well) or human leukocytes from healthy volunteers (5 × 10 4 cells/well) were seeded in 96-well plates and incubated for 24 hours in complete medium (DMEM or RPMI, respectively) with the anticancer agent (paclitaxel, oxaliplatin, or 5-fl uorouracil) alone or with varying amounts of oxidative stress modulators (mangafodipir, CuDIPS, MnTBAP, or N-acetylcysteine). Tumor cells and leukocytes from healthy volunteers were incubated with 10 and 20 μ M paclitaxel, 10 μ M and 1 mM oxaliplatin, or 50 μ M and 40 mM 5-fl uorouracil, respectively. Human leukocytes from cancer patients were incubated with 20, 30, and 40 μ M docetaxel alone or with 400 μ M mangafodipir. Cell viability was evaluated by the mitochondrion-dependent reduction of methylthiazoletetrazolium (MTT) to formazan. In brief, cells were exposed to 50 μ L of MTT (2 mg/mL in phosphate-buffered saline [PBS] ) and incubated for 4 hours at 37 °C. MTT reduction, which indicates viable cells, was visualized by addition of 100 μ L dimethyl sulfoxide. The ab sorbance at 550 nm in each well was recorded with an enzyme-linked immunosorbent assay (ELISA) microplate reader (VICTOR 2 ; Perkin Elmer, Paris, France). Results are expressed as percentage of viable cells compared with untreated cells (which have 100% viability).
In Vivo Hematologic Toxicity Analysis
BALB/c female mice between 6 and 8 weeks of age (Iffa Credo, L'Arbresles, France) were used in all experiments. Mice received humane care in compliance with institutional guidelines. PBS (1.54 mM potassium phosphate monobasic, 155.17 mM sodium chloride, 2.71 mM sodium phosphate dibasic; Life Technologies) at pH 7.2 was used as the vehicle. Mice were injected intraperitoneally with vehicle alone (group 1); with paclitaxel, mangafodipir, MnTBAP, CuDIPS, or N-acetylcysteine alone (groups 2 to 6); or with paclitaxel and one of the oxidative stress modulators in combination (groups 7 to 10). Five mice were treated in each group. Paclitaxel (20 mg/kg) or vehicle alone was administered on days 0, 2, and 4. This dose of paclitaxel was determined in previous experiments ( 6 ) and was used because it was associated with a 50% reduction in tumor volume of CT26 at day 15 without any substantial clinical toxicity. On days 0, 2, 4, and 7, mice were administered 10 mg/kg of mangafodipir, MnTBAP, or CuDIPS, 150 mg/kg of N-acetylcysteine, or vehicle. Ten days after the fi rst injection of paclitaxel or oxidative stress modulator, mice were killed by cervical dislocation. Spleen, bone marrow from femoral bone, and 1 mL of blood were then collected. The total number of hematopoietic cells in bone marrow and leukocytes from spleen and blood were counted using a Malassez cell.
Susceptibility of Mice to Bacterial Infection
In another experiment, BALB/c female mice were injected intraperitoneally with either vehicle alone (group 1), paclitaxel (60 mg/kg) alone on days 0, 3, and 6 (group 2), or paclitaxel (60 mg/ kg) in combination with mangafodipir (10 mg/kg) on days 0, 3, and 6 (group 3). A sublethal dose of the pathogen Staphylococcus aureus (200 μ L of a stock suspension with an optical density of 600 at 550 nm) was then injected intraperitoneally on day 9. The survival rate of mice was evaluated 48 hours following S. aureus injection. A total of 17 mice were treated in each group in three independent experiments.
In Vivo Antitumor Activity
Each BALB/c female mouse was injected subcutaneously in the back of the neck with 2 × 10 6 of CT26 cells. When the tumor reached a size of 200 -500 mm 3 , mice were grouped in 10 groups so that the sizes of the tumors were not statistically signifi cantly different by group. Mice were injected intraperitoneally with vehicle alone (group 1); with paclitaxel, mangafodipir, MnTBAP, CuDIPS, or N-acetylcysteine alone (groups 2 to 6); or with paclitaxel and one of these oxidative stress modulators in combination (groups 7 to 10). Paclitaxel (20 mg/kg) or vehicle was administered on days 0, 2, and 4. Then 10 mg/kg mangafodipir, MnTBAP, or CuDIPS or 150 mg/kg N-acetylcysteine or vehicle were administered three times a week for 1 month. Ten mice were treated in each group. Tumor size was measured with a Vernier calliper every 3 days at the same time that the oxidative stress modulator was administered. Tumor volume (TV) was calculated as follows: TV (mm 3 ) = (L × W 2 )/2, where L is the longest and W the shortest radius of the tumor. Results are expressed as the mean of tumor volume within each group. Tumor volumes were compared across treatment groups after each tumor size measurement, i.e., every 3 days.
Intracellular Levels of Superoxide Anions, Hydrogen Peroxide, and Reduced Glutathione
Tumor cells (2 × 10 4 /well) or human leukocytes from one healthy volunteer (5 × 10 4 /well) were seeded in 96-well plates and incubated for 48 hours in complete medium with anticancer agents (oxaliplatin, paclitaxel, or 5-fl uorouracil) alone or in combination with 400 μ M mangafodipir, 100 μ M CuDIPS, 100 μ M MnTBAP, or 400 μ M N-acetylcysteine. Tumor cells and leukocytes were incubated with 10 and 20 μ M paclitaxel, 10 μ M and 1 mM oxaliplatin, or 50 μ M and 40 mM 5-fl uorouracil, respectively. Levels of intracellular superoxide anion (O 2 − ) and H 2 O 2 were assessed spectrofl uorometrically (VICTOR 2 ) by oxidation of dihydroethidium (DHE) (Molecular Probes, Leiden, The Netherlands) and of 2 ′ ,7 ′ -dichlorodihydrofl uorescein diacetate (H 2 DCFDA) (Molecular Probes), respectively. Cells were washed once with PBS and then incubated with either 250 μ M DHE or 200 μ M H 2 DCFDA in PBS for 1 hour at 37 °C. Excitation and emission wavelengths used were 500 and 605 nm for DHE and 490 and 535 nm for H 2 DCFDA, respectively. The number of adherent cells was evaluated by the crystal violet assay. In brief, cells were stained in 0.5% crystal violet and 30% ethanol in PBS for 30 minutes at room temperature. After two washes in PBS, the stain was dissolved in 50% ethanol, and absorbance was measured at 560 nm on an ELISA multiwell reader. The levels of O 2 − or H 2 O 2 were calculated in each sample as follows: reactive oxygen species rate (arbitrary units/min/10 6 cells) = (fl uorescence intensity [arbitrary units] at T 60 minutesfl uorescence intensity [arbitrary units] at T 0 )/60 minutes/ number of adherent cells as measured by the crystal violet assay. Levels of intracellular reduced glutathione were assessed spectrofl uorometrically by monochlorobimane staining ( 23 ) . Briefl y, tumor cells (2 × 10 4 /well) or human leukocytes (5 × 10 4 /well) were seeded in 96-well plates and incubated for 48 hours in complete medium with anticancer agent alone or in combination with an oxidative stress modulator at the concentrations described above. Cells were washed once with PBS and then incubated with 50 μ M monochlorobimane diluted in PBS. The fl uorescence intensity was measured after 15 minutes at 37 °C. Excitation and emission wavelengths were 380 and 485 nm, respectively. The intracellular glutathione level was expressed as arbitrary units of fl uorescence intensity/number of adherent cells as measured by the crystal violet assay.
Statistical Analysis
All values from the in vitro experiments, except for those using leukocytes from cancer patients, are the mean values from three independent experiments, each carried out in triplicate. Data obtained using leukocytes from cancer patients are the mean values from the 10 cancer patients from one experiment carried out in triplicate. Error bars in the fi gures represent 95% confidence intervals (CIs) and are shown when larger than the symbol. Differences between treated and untreated groups were analyzed by the chi-square test for categorical data and by the Student's t test for comparison of means. P values less than .05 were considered statistically signifi cant.
R ESULTS
In Vitro Effect of Mangafodipir and Other Oxidative Stress Modulators on Human Leukocytes Treated With Anticancer Agents
We fi rst investigated the effect of oxidative stress modulators on anticancer drug -induced cytotoxicity of normal leukocytes. Leukocytes from six healthy volunteers were exposed in vitro to the alkylating agent oxaliplatin, the taxane paclitaxel, or the antimetabolite 5-fl uorouracil at concentrations approaching IC 50 values for 24 hours in the presence or absence of mangafodipir. In one representative healthy volunteer ( Fig. 1, A -C ) , concomitant exposure to increasing concentrations of mangafodipir statistically signifi cantly decreased the cytotoxicity of these three anticancer agents in a dose-dependent fashion compared with any of the anticancer agents alone. For example, a concentration of 400 μ M mangafodipir led to an absolute increase in cell survival of 46% (95% CI = 44% to 48%), 30.5% (95% CI = 29% to 32%), and 15% (95% CI = 10% to 20%) after 24 hours of exposure to 20 μ M paclitaxel, 1 mM oxaliplatin, or 40 mM 5-fl uorouracil, respectively, compared with survival of cells treated with each drug alone. N-Acetylcysteine displayed a similar protective effect against the cytotoxicity of paclitaxel, oxaliplatin, and 5-fl uorouracil toward human normal leukocytes. By contrast, CuDIPS and MnTBAP statistically signifi cantly enhanced the cytotoxicity of paclitaxel, oxaliplatin, and 5-fl uorouracil against leukocytes, although the effects were more pronounced with CuDIPS than with MnTBAP ( Fig. 1, A -C ) . Thus, concomitant treatment with 100 μ M CuDIPS or MnTBAP decreased cell survival by 44% (95% CI = 43% to 45%) and 3.6% (95% CI = 2.9% to 4.3%) after exposure to paclitaxel for 24 hours, respectively, compared with survival of cells treated with paclitaxel alone. We also assessed whether mangafodipir was effective in protecting leukocytes from the toxic effects of another taxane, docetaxel. Mangafodipir protected the leukocytes from the 10 cancer patients against the toxicity of docetaxel. Simultaneous incubation for 24 hours with 20 μ M docetaxel and 400 μ M mangafodipir increased the viability rate by 19.5% (95% CI = 16% to 23%) compared with the rate of cells incubated with docetaxel alone. We next investigated the effect of mangafodipir and three other oxidative stress modulators in combination with paclitaxel in BALB/c mice. After 10 days of treatment with paclitaxel alone (group 2), a statistically signifi cant decrease in the abso lute number of peripheral lymphocytes, neutrophils, and monocytes was observed in blood drawn from treated mice compared with blood drawn from control mice (group 1) ( Table 1 ) . This decrease was accompanied by a decrease in total bone marrow cell numbers. Administering mangafodipir (group 7) or N-acetylcysteine (group 10) in combination with paclitaxel abrogated the hematologic toxicity of paclitaxel. Neither mangafodipir nor N-acetylcysteine seemed to enhance hematopoiesis by itself. Indeed, blood and bone marrow cell counts in mice treated with mangafodipir (group 3) or N-acetylcysteine (group 6) alone were similar to those in untreated mice. By contrast to mangafodipir, the two other SOD mimics, CuDIPS (group 8) and MnTBAP (group 9), did not alter the hematologic toxicity of paclitaxel.
Because bacterial infection is the main complication of neu tropenia, the susceptibility of mice to S. aureus was tested after administration of paclitaxel alone (group 2) or in combination with mangafodipir (group 3) ( Table 2 ) . No deaths were observed in untreated mice inoculated with a sublethal dose of S. aureus . By contrast, 14 of 17 mice died within 48 hours after inoculation with the same dose of S. aureus following treatment with paclitaxel at a dose that induced neutropenia. However, only three of 17 mice inoculated with the bacteria died when mangafodipir had been administered in combination with paclitaxel ( P <.001).
Effect of Mangafodipir on Cytotoxicity of Anticancer Agents Against CT26 Cancer Cells In Vitro
Mangafodipir, as well as CuDIPS and MnTBAP, statistically signifi cantly increased the cytotoxicity of oxaliplatin ( Fig. 1, D ) , paclitaxel ( Fig. 1, E ) , and 5-fl uorouracil ( Fig. 1, F ) toward mouse CT26 colon cancer cells in a dose-dependent fashion. Conversely, N-acetylcysteine decreased the cytotoxicity of oxaliplatin, 5 -fl uorouracil, and paclitaxel toward CT26 cancer cells ( Fig. 1, D -F ) . Similar results were observed using murine hepatoma Hepa1.6 and human lung cancer A549 cell lines (data not shown).
Effect of Mangafodipir and Other Oxidative Stress Modulators in Mice Implanted with CT26 Tumor Cells and Treated With Paclitaxel
To determine whether oxidative stress modulators inhibit tumor growth, we next treated mice bearing CT26 tumors with either paclitaxel, mangafodipir, MnTBAP, CuDIPS, or N-acetylcysteine alone or with paclitaxel in combination with one of these oxidative stress modulators ( Fig. 2 ) . Mice treated with paclitaxel alone (group 2) developed smaller tumors than untreated mice (group 1), but the difference was statistically signifi cant only at day 27 and not before or after ( − 37%, 95% CI = − 7% to − 67%, P = .02 versus untreated mice at day 27). Mangafodipir inhibited tumor growth when administered alone (group 3) to a similar extent as paclitaxel ( Fig. 2, A ) ( − 34%, 95% CI = − 2% to − 66% at day 27, P = .05 versus untreated mice). Mice treated simultaneously with mangafodipir and paclitaxel (group 7) had statistically signifi cantly smaller tumors than untreated mice at days 24, 27, and 30 ( − 49%, 95% CI = − 7% to − 91%, P = .04 at day 27). The concentrations of mangafodipir and paclitaxel slightly amplifi ed the antitumor effect seen with paclitaxel alone, but the difference was not statistically signifi cant. CuDIPS (group 4) and MnTBAP (group 5) had only minimal antitumoral effects when administered alone and did not amplify the antitumoral effect of paclitaxel ( Fig. 2, B and C ) . By contrast, mice treated with N-acetylcysteine alone (group 6) developed larger tumors than untreated mice, but the difference was not statistically signifi cant ( Fig. 2, D ) . Adding N-acetylcysteine to paclitaxel (group 10) abrogated the antitumor effect of paclitaxel ( Fig. 2, D ) .
Effect of Mangafodipir and Other Oxidative Stress Modulators on Intracellular H 2 O 2 and O 2 − Generation in Normal and Cancer Cells Exposed to Anticancer Agents In Vitro
We next investigated the effects of mangafodipir and other oxidative stress modulators on levels of reactive oxygen species in cancer cell lines and normal leukocytes. Basal H 2 O 2 and O 2 − levels were lower in normal human leukocytes than in CT26 cancer cells ( Table 3 ) ( P <.001). Exposure to oxalipla tin, paclitaxel, or 5-fl uorouracil for 48 hours statistically signifi cantly increased intracellular levels of O 2 − and H 2 O 2 in both types of cells. (All comparisons between treated and untreated cells reached P <.001, with the exception of 5-fl uorouracil, for which P = .005 and P = .03 for H 2 O 2 and O 2 − levels, respectively). However, reactive oxygen species levels remained lower in normal leukocytes than in cancer cells after exposure to these agents ( Table 3 ). Exposure to these anticancer agents for 48 hours also statistically significantly decreased the intracellular reduced glutathione pool by 30% to 40% in both cancer and normal cells compared with untreated cells (both P <.005). Similar results were observed with Hepa1.6 cells (data not shown).
Simultaneous treatment of CT26 cells and human leukocytes with mangafodipir, CuDIPS, or MnTBAP decreased O 2 − accumulation induced by all three anticancer agents by 20% to 30% in cancer cells ( P <.01 compared with cells treated with anticancer agents alone). N-Acetylcysteine did not alter the O 2 − level in cells treated with anticancer agents.
In CT26 cancer cells, CuDIPS, MnTBAP, and mangafodipir increased H 2 O 2 accumulation ( Fig. 3 , A -C ) and glutathione depletion ( Fig. 4, A -C ) induced by oxaliplatin, paclitaxel, and 5-fl uorouracil. Similar results were obtained when the same set of experiments were conducted in Hepa1.6 cancer cells (data not shown). By contrast, in normal human leukocytes treated with paclitaxel, concomitant exposure to mangafodipir led to a 33% decrease in H 2 O 2 accumulation (95% CI = 29% to 37%, P <.001) compared with normal human leukocytes treated with paclitaxel alone, whereas concomitant exposure to CuDIPS or MnTBAP led to 28% (95% CI = 27% to 29%, P <.001) and 34% (95% CI = 29% to 39%, P <.001) increases in H 2 O 2 accumulation, respectively ( Fig. 3, E -G ) .
Glutathione is an essential cofactor in H 2 O 2 catabolism. Exposure to mangafodipir increased glutathione levels by 45% (95% CI = 40% to 50%, P <.001) in leukocytes also exposed to paclitaxel, whereas CuDIPS and MnTABP decreased glutathione levels by 15% (95% CI = 10.5% to 19.5%, P <.001) and 26.5% (95% CI = 15% to 38%, P <.001), respectively, when compared with leukocytes exposed to paclitaxel alone ( Fig. 4, E -G ) . Similar effects of mangafodipir were observed in cells treated with oxaliplatin or 5-fl uorouracil ( Fig. 4, G * BALB/c female mice were injected intraperitoneally with 60 mg/kg paclitaxel (on day [D] 0, D3, D6) alone or in combination with 10 mg/kg mangafodipir (D0, D3, D6). One group of mice remained untreated. A sublethal dose of the pathogen S. aureus was injected intraperitoneally at D9 to all mice, and the survival rate was evaluated at 48 hours. A total of 17 mice were treated in each group in three independent experiments. † BALB/c female mice were injected intraperitoneally with 20 mg/kg paclitaxel (on day [D] 0, D2, D4) and/or 10 mg/kg mangafodipir, MnTBAP, or CuDIPS or 150 mg/kg N-acetylcysteine (NAC) (D0, D2, D4, D7). One group of mice remained untreated. Five mice were treated in each group. All mice were killed on day 10 and spleen cells, bone marrow cells, and blood leukocytes were counted.
‡ All P values from Student's t test; comparison group was mice treated with paclitaxel alone. 
D ISCUSSION
We report what is, to our knowledge, the fi rst evidence that mangafodipir, a molecule that is currently used as a contrast agent for magnetic resonance imaging, has properties that may be useful in cancer therapy. We observed that mangafodipir protected human peripheral blood leukocytes drawn from healthy volunteers and cancer patients from the toxicity of several different anticancer agents that have distinct mechanisms of action. We also observed that mangafodipir protected BALB/c mice treated with paclitaxel from developing leukopenia infections and also amplifi ed the antitumoral effect of paclitaxel toward implanted tumors.
To investigate whether the SOD-, catalase-, and glutathione reductase -like activities of mangafodipir were responsible for its protective action, three other oxidative stress modulators -N-acetylcysteine, CuDIPS, and MnTBAP -were also studied to determine whether they protected leukocytes against toxicity from anticancer agents. In our in vitro experiments, N-acetylcysteine, like mangafodipir, protected normal leukocytes from the cytotoxic effects of paclitaxel, oxaliplatin, and 5-fl uorouracil. By contrast, CuDIPS and MnTBAP enhanced the toxicity of these drugs in leukocytes. The absence of a protective effect of the latter two compounds may be due to their lack of glutathione reductase activity, which reduces their capacity to detoxify H 2 O 2 . By contrast, the protective effect of mangafodipir and N-acetylcysteine could mangafodipir and paclitaxel dramatically improved the survival rate of mice infected with S. aureus . N-Acetylcysteine also had protective effects similar to those of mangafodipir, in agreement with previous data showing that N-acetylcysteine can abrogate the hematologic toxicity of alkylators in mice ( 24 ) . However, the use of N-acetylcysteine in association with anticancer drugs has been limited by its capacity to accelerate tumor growth, which neutralizes the antitumoral activity of the drugs ( 6 , 8 ) .
Other nonpeptidyl SOD mimics have also been shown to decrease the toxicity of anticancer agents or ionizing radiation in normal cells ( 25 -27 ) . For example, M40403, a pure MnSOD mimic, is able to block interleukin-2 -induced hypotension in mice, presumably by scavenging extracellular interleukin-2 -induced O 2 − , which inactivates circulating catecholamines ( 25 , 26 ) . Moreover, in a randomized trial, orgotein, a Cu/ ZnSOD mimic that does not cross cell membranes, abrogated the late but not the acute side effects of pelvic irradiation ( 27 ) . This protective effect of orgotein was attributed to the inhibition of the acute-phase infl ammatory events mediated by radiationinduced O 2 − . The two pure SOD mimics explored in these studies prevented specifi c side effects related to extracellular O 2 − accumulation, whereas in this study, mangafodipir was observed to prevent hematologic toxicity related to intracellular H 2 O 2 accumulation.
One major concern of the fi nding that mangafodipir prevents hematologic toxicity induced by anticancer agents is the possibility that mangafodipir could abrogate the toxicity of anticancer agents in cancer cells, as it does in normal cells. However, under the same in vitro experimental conditions as above, mangafodipir enhanced the antitumoral activity of the three agents tested. In vivo, mangafodipir abrogated the growth of implanted tumors when administered alone and enhanced the antitumoral effects of paclitaxel in combination. Therefore, mangafodipir may enhance the therapeutic index of anticancer agents by both protecting normal cells and increasing the antitumoral activity of these agents.
The opposing effects of mangafodipir in normal and cancer cells may be related to differences in the redox status of these cells. Indeed, we have confi rmed here that the basal concentration of reactive oxygen species and particularly of H 2 O 2 is higher in cancer cells than in normal cells ( 6 ) . The higher oxidative stress in tumor cells seems to be related to a higher rate of production of superoxide anions by the respiratory chain ( 6 , 28 ) and cytoplasmic NADPH oxidase ( 29 ) . Furthermore, tumor cells express lower levels of catalase, glutathione peroxidase, reductase, and their respective cofactors than normal cells ( 6 , 10 , 30 , 31 ) . Because anticancer agents induce the generation of H 2 O 2 in both normal and cancer cells ( 5 , 6 ) , the threshold of toxicity is reached more easily in cancer cells than in normal cells ( 6 ) . This difference leads to preferential inhibition of cell proliferation and increasing cell death in cancer cells.
A limitation of our study is that the antitumoral effect of mangafodipir was studied only in established tumor cell lines. Further studies are warranted to evaluate its activity against primary human tumors. Moreover, relatively high doses of mangafodipir were used in mice compared with those used in the imagery diagnostic setting. Associations between pharmacokinetic and pharmacodynamic parameters need to be evaluated in animals and in humans. Similar observations were made in vivo in mice treated with the hematotoxic anticancer agent paclitaxel. Simultaneous administration of mangafodipir, but not of CuDIPS or MnTBAP, protected mice from paclitaxel-induced hematologic and bone marrow toxicities at day 10. Moreover, coadministration of
In conclusion, our results support investigation of the use of mangafodipir in cancer patients, because mangafodipir may enhance the therapeutic index of anticancer agents by both protecting normal cells and increasing the antitumoral activity of these agents. The safety of mangafodipir administered as a contrast agent in magnetic resonance imaging has already been demonstrated ( 32 ) . Clinical studies are planned to evaluate the safety of repeated administrations of mangafodipir in human subjects and their ability to reproduce the biologic and clinical activities observed in mice. . Levels of intracellular glutathione were assessed spectrofl uorometrically using monochlorobimane. The glutathione level in cells treated with anticancer agents plus mangafodipir, CuDIPS, MnTBAP, or NAC was expressed as a mean percentage of glutathione levels + 95% confi dence intervals. All values are the mean values from three independent experiments carried out in triplicate. *.01< P <.05, **.001 ≤ P <.01, *** P <.001 by Student's t test when cells treated with both an anticancer agent plus one of the oxidative stress modulator were compared with cells not incubated with an oxidative stress modulator. 
